GLPwatch

Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor.

Nat Commun · 2021

Last updated 2026-05-28

Researchers studied how a compound called 'compound 2' interacts with the GLP-1 receptor, a protein linked to metabolic disorders. They found that compound 2 binds to the receptor and helps it work better by enhancing the effects of other molecules that control blood sugar. The study used advanced imaging to show how this compound changes the shape of the receptor, making it more effective at activating the receptor.

AI summary of the abstract below.

JournalNat Commun, 2021
Citations66
Relative citation ratio3.92
NIH percentile89
Molecules
Conditions studied Type 2 Diabetes, Obesity

Abstract

The glucagon-like peptide-1 (GLP-1) receptor is a validated drug target for metabolic disorders. Ago-allosteric modulators are capable of acting both as agonists on their own and as efficacy enhancers of orthosteric ligands. However, the molecular details of ago-allosterism remain elusive. Here, we report three cryo-electron microscopy structures of GLP-1R bound to (i) compound 2 (an ago-allosteric modulator); (ii) compound 2 and GLP-1; and (iii) compound 2 and LY3502970 (a small molecule agonist), all in complex with heterotrimeric G. The structures reveal that compound 2 is covalently bonded to C347 at the cytoplasmic end of TM6 and triggers its outward movement in cooperation with the ECD whose N terminus penetrates into the GLP-1 binding site. This allows compound 2 to execute positive allosteric modulation through enhancement of both agonist binding and G protein coupling. Our findings offer insights into the structural basis of ago-allosterism at GLP-1R and may aid the design of better therapeutics.

Verbatim abstract via PubMed 34145245 ↗